Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Meningococcal Disease
Research on meningococcal disease published by T. Siu et al
January 7th, 2009
"1) To examine trends in serogroup-specific invasive meningococcal disease (IMD) incidence associated with the protein-polysaccharide conjugate C vaccine (MCC) program in BC; 2) To assess for evidence of capsule switching and serogroup replacement,3) To discuss whether recent data support modification of the current MCC program to include the quadrivalent protein-polysaccharide conjugate vaccine (MCV-4). Information on IMID cases since 1998 were extracted from surveillance databases," researchers in Vancouver, Canada report. "Annual IMD incidence rates and corresponding three-year moving averages were calculated. Data management was performed using Microsoft (R) Office...
Source: Vaccine Weekly (2009-01-07)
|
